ClinicalTrials.gg
TerminatedNCT02862535Updated Dec 24, 2020Results posted

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 1 interventional study of Andecaliximab and S-1 in Gastric Adenocarcinoma, sponsored by Gilead Sciences. Terminated at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-12-24.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Why this study was terminated
Study was terminated due to sponsor's decision to not pursue further development of andecaliximab in oncology

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Study summary

The primary objective of this study is to characterize the safety and tolerability of andecaliximab as monotherapy and in combination with anti-cancer agents in Japanese participants with inoperable advanced or recurrent gastric or recurrent gastroesophageal junction (GEJ) adenocarcinoma.

02

Conditions studied

  • Gastric Adenocarcinoma
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have been born in Japan and must not have lived outside of Japan for a period > 1 year in the 5 years prior to Day 1
  • Must be able to trace their maternal and paternal ancestry of parents and grandparents as ethnically Japanese
  • confirmed inoperable advanced gastric adenocarcinoma (including adenocarcinoma of the GEJ) or gastric adenocarcinoma
  • Cohorts 1, 2, and 3: Human Epidermal Growth Factor Receptor 2 ()-negative tumor (primary tumor or lesion). Enrollment in Cohort 4 is not restricted by HER2 status (adults with HER2-positive, HER2-negative, or unknown HER2 status are eligible)
  • Cohort 1: Prior antitumor therapy or cytotoxic chemotherapy is acceptable. Individuals who are not eligible to receive standard treatments should enroll on the study.
  • Cohorts 2 and 3: Prior antitumor therapy or cytotoxic chemotherapy for metastatic disease is not acceptable. Individuals must be chemo-naive in the metastatic setting
  • (ECOG) Performance Status of ≤ 1
  • Adequate baseline organ function (within 28 days prior to Day 1)
  • Coagulation: (INR) ≤ 1.5 (unless receiving anticoagulation therapy)
  • For females of , willingness to use a protocol-recommended method of from the screening visit throughout the study treatment period and for defined periods following the last dose of andecaliximab and/or anti-cancer agent(s)
  • For males of childbearing potential having intercourse with females of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of andecaliximab, throughout the study treatment period, and for protocol defined periods following the last dose of andecaliximab and/or anti-cancer agent(s)
  • Willingness to comply with scheduled visits, drug administration plan, imaging studies, laboratory tests, other study procedures, and study restrictions
  • In addition to the applicable criteria above, participants in Cohort 4 must meet additional inclusion criteria to be eligible for participation in this study:

    • Measurable gastric or GEJ adenocarcinoma
    • Must have progressed on at least 1 prior systemic therapy or for unresectable/metastatic disease.
    • Activated partial thromboplastin (aPTT) ≤ 1.5 times the
    • Thyroid function tests should be within normal limits.

Key Exclusion Criteria:

  • History or evidence of a disorder, condition, or disease that, in the opinion of the investigator and medical monitor would pose a risk to participant safety or interfere with the study evaluations, procedures, or completion
  • Pregnant or lactating. Enrollment of lactating females after discontinuation of breastfeeding is not acceptable.
  • Individuals with known central nervous system (CNS) metastases, unless metastases are treated and stable and the individual does not require systemic
  • Radiotherapy within 28 days of Day 1
  • Myocardial infarction, symptomatic congestive heart failure ( Classification > Class II), unstable angina, or serious uncontrolled cardiac arrhythmia within the last 6 months of Day 1
  • History of major surgery within 28 days of Day 1
  • Serious systemic fungal, bacterial, viral, or other infection that is not controlled or requires IV antibiotics
  • Individuals known to be positive for (HIV), infection (per local standard diagnostic criteria), or acute or chronic infection (per local standard diagnostic criteria)
  • In addition to the applicable criteria above, participants in Cohort 4 who meet any of the following exclusion criteria will not be enrolled in this study

    • Have received only or adjuvant therapy for gastric adenocarcinoma
    • Prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 () agents, anti-programmed cell death protein 1 (anti PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agents, anti-programmed cell death ligand 2 (anti-PD-L2) agents, anti-matrix metalloprotease (anti-MMP) agents, or other immunomodulatory therapies

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Cohort 1: ADX

    Participants will receive andecaliximab (ADX) 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab

  • Experimental
    Cohort 2: ADX + S-1 + Cisplatin

    Participants will receive ADX 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle in combination with S-1 orally twice daily plus cisplatin chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice, and/or the in-country label) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: S-1 · Drug: Cisplatin

  • Experimental
    Cohort 3: ADX + S-1 + Oxaliplatin

    Participants will receive ADX 1200 mg every 3 weeks on Day 1 of each 21-day treatment cycle in combination with chemotherapy (S-1 80 mg/day to 120 mg/day according to the body surface area orally twice daily for first 14 days of 21 day cycle plus oxaliplatin 100 mg/m\^2) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study.

    Drug: Andecaliximab · Drug: S-1 · Drug: Oxaliplatin

  • Experimental
    Cohort 4: ADX + Nivolumab

    Participants will receive ADX 800 mg every 2 weeks followed by chemotherapy (nivolumab 3 mg/kg) on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.

    Drug: Andecaliximab · Drug: Nivolumab

Interventions

  • Administered via intravenous (IV) infusion (approximately 30 minutes)

    Also known as: GS-5745

  • DrugS-1

    Drug pages: Tegafur · Gimeracil · Oxonic Acid

    Administered orally

  • Administered via IV infusion on Day 8 of every 5 weeks

  • Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle

  • Administered via IV infusion (approximately 60 minutes) every 2 weeks

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

    TEAEs are any AEs with an onset date of on or after the date that ADX and if applicable, nivolumab was first administered and no later than 30 days after permanent discontinuation of ADX, or if applicable, 5 months after permanent discontinuation of nivolumab (whichever is later).

    Time frame: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)

  2. Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

    Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the specified time frame (first dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)) was considered treatment-emergent.Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 was used for assigning toxicity grades to laboratory results for analysis.

    Time frame: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)

Secondary outcomes

  1. Cohort 1: Plasma Concentration of Andecaliximab

    Plasma concentration is defined as the measured drug concentration. Blood samples were drawn at pre-dose and 30 (±15) minutes after infusion on Day 1 of Cycles 2, 3, 5; End of study (EOS) (3 years and 1 month); Cycle 1 only: 30 (±15) minutes after infusion on Day 1; anytime on Day 2, 4, and 8; pre-dose and 30 (±15) minutes post infusion on Day 15. The duration of each cycle for Cohort 1, 2, and 4 was 28 days and for Cohort 3 was 21 days. Infusion duration = 30 to 35 minutes. * min=minutes * D=Days * C=Cycle

    Time frame: Pre-dose and 30 (±15) min after infusion on C2D1, C3D1, C5D1; EOS (3 years and 1 month); C1 only: 30 (±15) min after infusion on D1; anytime on D2, D4 and D8; Pre-dose and 30 (±15) minutes post infusion on D15

  2. PK Parameter: Cmax of Andecaliximab

    Cmax is defined as the maximum concentration of drug.

    Time frame: Cycle 1 only: 30 (± 15) minutes after the end of infusion on Day 1; anytime on Days 2, 4, and 8; prior to dosing on Day 15 (Cycle length= 28 days) (infusion duration= 30 to 35 minutes)

  3. PK Parameter: AUClast of Andecaliximab

    AUClast is defined as the area under the concentration versus time curve to the last measurable concentration of drug from time zero to the last observable concentration.

    Time frame: Cycle 1 only: 30 (± 15) minutes after the end of infusion on Day 1; anytime on Days 2, 4, and 8; prior to dosing on Day 15 (Cycle length= 28 days) (infusion duration= 30 to 35 minutes)

  4. PK Parameter: AUC0-336h of Andecaliximab

    AUC0-336h is defined as the area under the concentration versus time curve from time zero to time 336 hour.

    Time frame: Cycle 1 only: 30 (± 15) minutes after the end of infusion on Day 1; anytime on Days 2, 4, and 8; prior to dosing on Day 15 (Cycle length= 28 days) (infusion duration= 30 to 35 minutes)

  5. Number of Participants With Positive Anti-Andecaliximab Antibodies

    Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 5, 7 and every third cycle and anytime at EOT (82.4 weeks) and EOS visit (maximum: 3 years and 1 month) (Each Cycle= 28 days for Cohort 1, 2 and 4; 21 days for Cohort 3)

07

Results

Posted Dec 24, 2020

Participant flow

Participants were enrolled at study sites in Japan. The first participant was screened on 20 Sep 2016. The last study visit occurred on 25 Oct 2019.

Participant flow — Overall Study
MilestoneCohort 1: ADXCohort 2: ADX + S-1 + CisplatinCohort 3: ADX + S-1 + OxaliplatinCohort 4: ADX + Nivolumab
Started961011
Completed0000
Not completed961011
Withdrew: Death7325
Withdrew: Study terminated by sponsor1385
Withdrew: Enrolled, not treated1001

Outcome measures

PrimaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)

TEAEs are any AEs with an onset date of on or after the date that ADX and if applicable, nivolumab was first administered and no later than 30 days after permanent discontinuation of ADX, or if applicable, 5 months after permanent discontinuation of nivolumab (whichever is later).

Time frame:
First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
percentage of participantsCohort 1: ADXCohort 2: ADX + S-1 + CisplatinCohort 3: ADX + S-1 + OxaliplatinCohort 4: ADX + Nivolumab
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)100.0100.0100.0100.0
PrimaryPercentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the specified time frame (first dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)) was considered treatment-emergent.Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 was used for assigning toxicity grades to laboratory results for analysis.

Time frame:
First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
percentage of participantsCohort 1: ADXCohort 2: ADX + S-1 + CisplatinCohort 3: ADX + S-1 + OxaliplatinCohort 4: ADX + Nivolumab
Any Laboratory abnormalities: Hematology87.583.390.070.0
Any Laboratory abnormalities: Chemistry100.0100.0100.080.0
Any Laboratory abnormalities: Coagulation00010.0
SecondaryCohort 1: Plasma Concentration of Andecaliximab

Plasma concentration is defined as the measured drug concentration. Blood samples were drawn at pre-dose and 30 (±15) minutes after infusion on Day 1 of Cycles 2, 3, 5; End of study (EOS) (3 years and 1 month); Cycle 1 only: 30 (±15) minutes after infusion on Day 1; anytime on Day 2, 4, and 8; pre-dose and 30 (±15) minutes post infusion on Day 15. The duration of each cycle for Cohort 1, 2, and 4 was 28 days and for Cohort 3 was 21 days. Infusion duration = 30 to 35 minutes. * min=minutes * D=Days * C=Cycle

Time frame:
Pre-dose and 30 (±15) min after infusion on C2D1, C3D1, C5D1; EOS (3 years and 1 month); C1 only: 30 (±15) min after infusion on D1; anytime on D2, D4 and D8; Pre-dose and 30 (±15) minutes post infusion on D15
Reported as:
Mean · nanograms per milliliter
Cohort 1: Plasma Concentration of Andecaliximab
nanograms per milliliterCohort 1: ADX
30 minutes Postdose: Cycle 1 Day 1262,625.0 ± 57410.64
Postdose: Cycle 1 Day 2211,875.0 ± 56688.21
Postdose: Cycle 1 Day 4133,100.0 ± 57485.39
Postdose: Cycle 1 Day 890100.0 ± 18127.25
Predose: Cycle 1 Day 1554800.0 ± 12011.66
30 minutes Postdose: Cycle 1 Day 15310,971.4 ± 128,365.39
Predose: Cycle 2 Day 1122,200.0 ± 52872.68
30 minutes Postdose: Cycle 2 Day 1458,666.7 ± 211,613.64
Predose: Cycle 3 Day 1158,000.0 ± 16970.56
30 minutes Postdose: Cycle 3 Day 1349,300.0 ± 402,626.60
Predose: Cycle 5 Day 1154,500.0 ± 6363.96
30 minutes Postdose: Cycle 5 Day 1510,500.0 ± 136,471.61
End of study61960.0 ± 37635.40
SecondaryPK Parameter: Cmax of Andecaliximab

Cmax is defined as the maximum concentration of drug.

Time frame:
Cycle 1 only: 30 (± 15) minutes after the end of infusion on Day 1; anytime on Days 2, 4, and 8; prior to dosing on Day 15 (Cycle length= 28 days) (infusion duration= 30 to 35 minutes)
Reported as:
Mean · micrograms per milliliter
PK Parameter: Cmax of Andecaliximab
micrograms per milliliterCohort 1: ADX
PK Parameter: Cmax of Andecaliximab264.0 ± 56.42
SecondaryPK Parameter: AUClast of Andecaliximab

AUClast is defined as the area under the concentration versus time curve to the last measurable concentration of drug from time zero to the last observable concentration.

Time frame:
Cycle 1 only: 30 (± 15) minutes after the end of infusion on Day 1; anytime on Days 2, 4, and 8; prior to dosing on Day 15 (Cycle length= 28 days) (infusion duration= 30 to 35 minutes)
Reported as:
Mean · hours*micrograms per milliliter(h*μg/mL)
PK Parameter: AUClast of Andecaliximab
hours*micrograms per milliliter(h*μg/mL)Cohort 1: ADX
PK Parameter: AUClast of Andecaliximab33500.2 ± 8397.01
SecondaryPK Parameter: AUC0-336h of Andecaliximab

AUC0-336h is defined as the area under the concentration versus time curve from time zero to time 336 hour.

Time frame:
Cycle 1 only: 30 (± 15) minutes after the end of infusion on Day 1; anytime on Days 2, 4, and 8; prior to dosing on Day 15 (Cycle length= 28 days) (infusion duration= 30 to 35 minutes)
Reported as:
Mean · h*μg/mL
PK Parameter: AUC0-336h of Andecaliximab
h*μg/mLCohort 1: ADX
PK Parameter: AUC0-336h of Andecaliximab34341.9 ± 8697.66
SecondaryNumber of Participants With Positive Anti-Andecaliximab Antibodies
Time frame:
Pre-dose on Day 1 of Cycles 1, 2, 3, 5, 7 and every third cycle and anytime at EOT (82.4 weeks) and EOS visit (maximum: 3 years and 1 month) (Each Cycle= 28 days for Cohort 1, 2 and 4; 21 days for Cohort 3)
Reported as:
Count of participants · Participants
Number of Participants With Positive Anti-Andecaliximab Antibodies
ParticipantsCohort 1: ADXCohort 2: ADX + S-1 + CisplatinCohort 3: ADX + S-1 + OxaliplatinCohort 4: ADX + Nivolumab
Number of Participants With Positive Anti-Andecaliximab Antibodies0000

Adverse events

Collected over Adverse Events: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab) All-Cause Mortality: From study start date up to study completion date (3 years and 1 month). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: ADX7/8 (87.5%)2/8 (25%)8/8 (100%)
Cohort 2: ADX + S-1 + Cisplatin3/6 (50%)2/6 (33.3%)6/6 (100%)
Cohort 3: ADX + S-1 + Oxaliplatin2/10 (20%)1/10 (10%)10/10 (100%)
Cohort 4: ADX + Nivolumab5/10 (50%)5/10 (50%)10/10 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventCohort 1: ADXCohort 2: ADX + S-1 + CisplatinCohort 3: ADX + S-1 + OxaliplatinCohort 4: ADX + Nivolumab
Hepatic function abnormalHepatobiliary disorders0/81/60/100/10
Decreased appetiteMetabolism and nutrition disorders1/81/60/100/10
Back painMusculoskeletal and connective tissue disorders0/81/60/100/10
HydronephrosisRenal and urinary disorders1/80/60/100/10
AnaemiaBlood and lymphatic system disorders0/80/60/101/10
MalaiseGeneral disorders0/80/60/101/10
PyrexiaGeneral disorders0/80/60/101/10
Bile duct stenosisHepatobiliary disorders0/80/61/100/10
CholangitisHepatobiliary disorders0/80/60/101/10
Blood bilirubin increasedInvestigations0/80/60/101/10
Most frequent other events
Showing 10 of 108
Most frequent other events
EventCohort 1: ADXCohort 2: ADX + S-1 + CisplatinCohort 3: ADX + S-1 + OxaliplatinCohort 4: ADX + Nivolumab
Peripheral sensory neuropathyNervous system disorders0/81/610/101/10
NauseaGastrointestinal disorders4/85/64/102/10
Decreased appetiteMetabolism and nutrition disorders3/85/65/102/10
DiarrhoeaGastrointestinal disorders1/84/62/102/10
StomatitisGastrointestinal disorders0/83/63/103/10
Neutrophil count decreasedInvestigations0/83/63/102/10
Platelet count decreasedInvestigations0/81/65/100/10
White blood cell count decreasedInvestigations0/83/64/102/10
InsomniaPsychiatric disorders0/83/60/101/10
ConstipationGastrointestinal disorders2/82/64/101/10

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1: ADXCohort 2: ADX+S-1+CisplatinCohort 3: ADX+S-1+OxaliplatinCohort 4: ADX+NivolumabTotal
Mean59 ± 14.769 ± 7.956 ± 15.163 ± 11.861 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: ADXCohort 2: ADX+S-1+CisplatinCohort 3: ADX+S-1+OxaliplatinCohort 4: ADX+NivolumabTotal
Female31419
Male556925
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: ADXCohort 2: ADX+S-1+CisplatinCohort 3: ADX+S-1+OxaliplatinCohort 4: ADX+NivolumabTotal
Hispanic or Latino00000
Not Hispanic or Latino86101034
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: ADXCohort 2: ADX+S-1+CisplatinCohort 3: ADX+S-1+OxaliplatinCohort 4: ADX+NivolumabTotal
American Indian or Alaska Native00000
Asian86101034
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
08

Study locations

3 sites
  • Nagoya, Japan
  • Osaka, Japan
  • Tokyo, Japan
09

References and documents

Publications

  • Yamaguchi K, Satoh T, Muro K, Takashima A, Ichimura T, et al. Phase 1b Study of Andecaliximab as Monotherapy and in Combination With Nivolumab in Japanese Patients With Gastric or GEJ Adenoracinoma [Poster L9]. Presented at ASCO GI 2019 Gastrointestinal Cancers Symposium: Jan 17-19, 2019, San Francisco, CA, USA.
  • Muro K, Yamaguchi K, Satoh T, Kadowaki S, Ichimura T, et al. Phase 1b Study of Andecaliximab in Combination With S-1 + Platinum Chemotherapy in Japanese Patients With Advanced Gastric or GEJ Adenocarcinoma [Poster G3]. Presented at ASCO GI 2019 Gastrointestinal Cancers Symposium: Jan 17-19, 2019, San Francisco, CA, USA.
  • Muro K, Satoh T, Yamaguchi K, Kadowaki S, Sakai D, et al. Phase 1b Study of Andecaliximab (ADX) as Monotherapy and in Combination With Nivolumab (nivo) in Japanese Subjects With Gastric or GEJ Adenocarcinoma. Presented at the Japanese Gastric Cancer Association: Feb 28, 2019.
  • Satoh T, Yamaguchi K, Muro K, Sakai D, Ichimura T, et al. Phase 1b Study of Andecaliximab (GS-5745, ADX) in Combination With S-1 + Platinum Chemotherapy in Japanese Subjects With Advanced Gastric or GEJ Adenocarcinoma. Presented at the Japanese Gastric Cancer Association: Feb 28, 2019.
  • Ooki A, Satoh T, Muro K, Takashima A, Kadowaki S, Sakai D, Ichimura T, Mitani S, Kudo T, Chin K, Kitano S, Thai D, Zavodovskaya M, Liu J, Boku N, Yamaguchi K. A phase 1b study of andecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma. Sci Rep. 2022 Jun 30;12(1):11007. doi: 10.1038/s41598-022-13801-1. PubMed 35773363 ↗
  • Yoshikawa AK, Yamaguchi K, Muro K, Takashima A, Ichimura T, Sakai D, Kadowaki S, Chin K, Kudo T, Mitani S, Kitano S, Thai D, Zavodovskaya M, Liu J, Boku N, Satoh T. Safety and tolerability of andecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. J Immunother Cancer. 2022 Jan;10(1):e003518. doi: 10.1136/jitc-2021-003518. PubMed 34992093 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2016 to primary completion in Oct 2019, 37 months.

Results were first posted in Dec 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2016
First posted
Aug 11, 2016
StartActual
Sep 20, 2016
Primary completionActual
Oct 25, 2019
CompletionActual
Oct 25, 2019
Results first posted
Dec 24, 2020
Last update
Dec 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02862535
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Aug 11, 2016
Start date
Sep 20, 2016
Primary completion
Oct 25, 2019
Completion
Oct 25, 2019
Results posted
Dec 24, 2020
Last update
Dec 24, 2020

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion